hVIVO acquires CRS Berlin to enter dermatology and women's health
hVIVO plc, the AIM-listed clinical development partner best known for its human challenge trial capability, has acquired CRS Clinical Research Services Berlin GmbH, adding specialist Phase I/II capacity in dermatology and women's health to its growing German network. The deal was announced on 27 August 2026 and follows hVIVO's acquisition of CRS Mannheim and CRS Kiel in January 2025.
The financial terms are structured to minimise upfront risk. hVIVO paid initial consideration of just €0.025 million and has agreed to pay 18% of CRS Berlin's annual revenue for each of the next three years, subject to minimum revenue thresholds. Management expects aggregate earnout payments of approximately €6 million in cash over that period, net of a €2 million pension liability assumed from the vendor, implying a total outlay to vendors of roughly €4 million. CRS Berlin reported unaudited revenues of €10 million and EBITDA of €0.3 million for 2025, and entered 2026 with a contracted orderbook of approximately €10 million, which the company says provides strong visibility against its forecast for the year.
The strategic rationale
For hVIVO, the deal is primarily about therapeutic area diversification. The group's existing early-phase expertise spans infectious disease, respiratory, cardiometabolic and immunology indications. Dermatology and women's health are additive rather than overlapping, and CRS Berlin is described by hVIVO as one of a small number of European Phase I units with an established track record across both. The 32-bed Berlin facility, which includes 18 intensive monitoring beds, has completed more than 350 studies under the leadership of Medical Director Dr Sybille Baumann, a board-certified anaesthesiologist and pharmacologist whose prior research contributions include co-authorship on COVID-19 vaccine publications in Nature and the New England Journal of Medicine.
Chief executive Yamin "Mo" Khan said the transaction terms reflect hVIVO's "disciplined approach to capital allocation," with earnout payments linked to CRS Berlin's future revenue rather than paid upfront. He added that the acquisition is expected to be self-funding, supported by the acquired orderbook and contracted revenues.
Operationally, the integration task appears limited. CRS Berlin has collaborated closely with hVIVO's Mannheim site since the earlier acquisition, with approximately 50% of Berlin's incoming proposals already submitted jointly with Mannheim. Participant recruitment, quality assurance, sales, marketing and IT infrastructure are described as already aligned across the CRS network.
Market context
The financial projections cited in the release illustrate why both therapeutic areas are attracting CRO investment. The global dermatology CRO market is valued at approximately US$6.1 billion in 2026 and is forecast to grow at a compound annual growth rate of around 6% to US$9.7 billion by 2034, according to Fortune Business Insights and Mordor Intelligence figures cited by hVIVO. The women's clinical trials and CRO segment is projected to expand from roughly US$9.9 billion in 2026 to US$22.3 billion by 2036, a CAGR of 8.5%, according to Visiongain.
Women's health in particular has historically been under-represented in early-phase trial design, a gap that regulators and sponsors have begun to address more systematically in recent years. The MHRA and FDA have both pushed for greater inclusion of women in early-phase protocols, and sponsor demand for sites with dedicated recruitment infrastructure and clinical expertise in this area has increased accordingly. For a CRO of hVIVO's size, securing a proven European Phase I site in this space before competition for such assets intensifies carries obvious strategic logic.
The broader consolidation trend among European early-phase CROs has been a feature of the sector for several years, with mid-sized operators seeking the multi-site scale that large sponsors increasingly prefer when awarding framework agreements. hVIVO's acquisitions of the three CRS sites in Germany position it to compete for larger, pan-European Phase I packages that a single-site operator could not support.